TG Therapeutics CEO Says Briumvi Is On Track To Become A $1B US Drug – Retail Shrugs Off EPS Miss

The biotech firm increased its 2026 total global revenue target to around $950 million, up from $925 million previously.
MarketBeat on MSN

TG Therapeutics Q2 Earnings Call Highlights

Key Points Interested in TG Therapeutics, Inc.? Here are five stocks we like better. Strong BRIUMVI growth lifted TG ...

TG Therapeutics targets $890M-$905M 2026 U.S. BRIUMVI net revenue while anticipating subcutaneous Phase III results around year-end

Q2 raised full-year guidance to "$890 million to $905 million" U.S. net revenue and "approximately $950 million" global revenue vs. Q1 guidance of "$885 million to $900 million" U.S. and ...

TG Therapeutics: Why I'm Staying Long After The Q2 Selloff

TG Therapeutics, Inc. stays a Buy as BRIUMVI revenue jumps and 2026 guidance rises; subcutaneous Phase 3 is a catalyst. Click ...
PC Magazine

OM System TG-7 Review

The OM System TG-7 is pretty much the same camera as the TG-6, which itself isn't very different than the TG-5. This relative lack of change is an effect of a shrinking compact camera market and ...